Ys Biopharma Co Stock Beneish M Score

YS Stock   0.94  0.09  10.59%   
This module uses fundamental data of YS Biopharma to approximate the value of its Beneish M Score. YS Biopharma M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out YS Biopharma Piotroski F Score and YS Biopharma Altman Z Score analysis.
  
At this time, YS Biopharma's Net Debt is comparatively stable compared to the past year. Debt To Equity is likely to gain to 0.65 in 2024, whereas Long Term Debt is likely to drop slightly above 201.2 M in 2024. At this time, YS Biopharma's Intangibles To Total Assets are comparatively stable compared to the past year. Current Ratio is likely to gain to 1.95 in 2024, whereas Free Cash Flow Yield is likely to drop (0.28) in 2024.
At this time, YS Biopharma's M Score is unavailable. The earnings manipulation may begin if YS Biopharma's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by YS Biopharma executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of YS Biopharma's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-3.16
Beneish M Score - Unavailable
Elasticity of Receivables

1.05

Focus
Asset Quality

N/A

Focus
Expense Coverage

1.77

Focus
Gross Margin Strengs

0.89

Focus
Accruals Factor

1.77

Focus
Depreciation Resistance

N/A

Focus
Net Sales Growth

0.67

Focus
Financial Leverage Condition

0.96

Focus

YS Biopharma Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if YS Biopharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables373.9 M532.5 M
Way Down
Slightly volatile
Total Revenue530.6 M790.3 M
Way Down
Slightly volatile
Total Assets1.6 BB
Significantly Down
Slightly volatile
Total Current Assets929.1 M1.2 B
Significantly Down
Slightly volatile
Non Current Assets Total658.1 M786.3 M
Fairly Down
Slightly volatile
Depreciation And Amortization35.1 M42.2 M
Significantly Down
Slightly volatile
Selling General Administrative87.4 M73.6 M
Fairly Up
Slightly volatile
Total Current Liabilities542.6 M757.6 M
Way Down
Slightly volatile
Non Current Liabilities Total284.3 M299.3 M
Notably Down
Slightly volatile
Short Term Debt116.7 M228.3 M
Way Down
Slightly volatile
Long Term Debt201.2 M337.9 M
Way Down
Slightly volatile
Gross Profit Margin0.620.7
Fairly Down
Slightly volatile

YS Biopharma Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between YS Biopharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards YS Biopharma in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find YS Biopharma's degree of accounting gimmicks and manipulations.

About YS Biopharma Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Current Deferred Revenue

2.46 Million

At this time, YS Biopharma's Current Deferred Revenue is comparatively stable compared to the past year.

About YS Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze YS Biopharma Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of YS Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of YS Biopharma Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards YS Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, YS Biopharma's short interest history, or implied volatility extrapolated from YS Biopharma options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether YS Biopharma is a strong investment it is important to analyze YS Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact YS Biopharma's future performance. For an informed investment choice regarding YS Biopharma Stock, refer to the following important reports:
Check out YS Biopharma Piotroski F Score and YS Biopharma Altman Z Score analysis.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for YS Biopharma Stock analysis

When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.56)
Revenue Per Share
5.159
Quarterly Revenue Growth
(0.50)
Return On Assets
(0.12)
Return On Equity
(0.62)
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.